Long‐term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders
Identifieur interne : 002D66 ( Main/Exploration ); précédent : 002D65; suivant : 002D67Long‐term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders
Auteurs : Christopher Kenney [États-Unis] ; Christine Hunter [États-Unis] ; Joseph Jankovic [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2007-01-15.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Adult, Age of Onset, Anti-Dyskinesia Agents (administration & dosage), Anti-Dyskinesia Agents (adverse effects), Anti-Dyskinesia Agents (therapeutic use), Chorea, Drug Administration Schedule, Drug Tolerance (physiology), Dyskinesia, Dyskinesia, Drug-Induced (drug therapy), Dyskinesia, Drug-Induced (epidemiology), Dyskinesia, Drug-Induced (physiopathology), Female, Humans, Huntington Disease (epidemiology), Huntington Disease (etiology), Huntington Disease (physiopathology), Hyperkinesia, Hyperkinesis (drug therapy), Hyperkinesis (epidemiology), Hyperkinesis (physiopathology), Long term, Male, Middle Aged, Myoclonus (drug therapy), Myoclonus (epidemiology), Myoclonus (physiopathology), Nervous system diseases, Parkinsonian Disorders (drug therapy), Parkinsonian Disorders (epidemiology), Parkinsonian Disorders (physiopathology), Prevalence, Retrospective Studies, Severity of Illness Index, Tetrabenazine, Tetrabenazine (administration & dosage), Tetrabenazine (adverse effects), Tetrabenazine (therapeutic use), Tic, Tics (drug therapy), Tics (epidemiology), Tics (physiopathology), Time, Treatment, chorea, tardive dyskinesia, tetrabenazine, tics, tolerability.
- MESH :
- chemical , administration & dosage : Anti-Dyskinesia Agents, Tetrabenazine.
- chemical , adverse effects : Anti-Dyskinesia Agents, Tetrabenazine.
- chemical , therapeutic use : Anti-Dyskinesia Agents, Tetrabenazine.
- drug therapy : Dyskinesia, Drug-Induced, Hyperkinesis, Myoclonus, Parkinsonian Disorders, Tics.
- epidemiology : Dyskinesia, Drug-Induced, Huntington Disease, Hyperkinesis, Myoclonus, Parkinsonian Disorders, Tics.
- etiology : Huntington Disease.
- physiology : Drug Tolerance.
- physiopathology : Dyskinesia, Drug-Induced, Huntington Disease, Hyperkinesis, Myoclonus, Parkinsonian Disorders, Tics.
- Adult, Age of Onset, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Prevalence, Retrospective Studies, Severity of Illness Index, Time.
Abstract
We sought to review the long‐term tolerability of tetrabenazine (TBZ) and seek determinants of tolerability in the treatment of hyperkinetic movement disorders. A retrospective chart review was performed on patients treated with TBZ between 1997 and 2004. Efficacy of TBZ was assessed by a 1‐ to 5‐point response scale (1 = marked reduction in abnormal movements, 5 = worsening). All adverse events (AEs) were captured according to their relationship with study drug. A total of 448 patients (42% male) were treated for a variety of hyperkinesias, including tardive dyskinesia (n = 149), dystonia (n = 132), chorea (n = 98), tics (n = 92), and myoclonus (n = 19). The mean age at onset of the movement disorder was 43.0 ± 24.2 years, with TBZ starting at a mean age of 50.0 ± 22.3 years. Patients remained on treatment for a mean of 2.3 ± 3.4 years. An efficacy response rating of 1 or 2 was sustained in the majority of patients between the first and last visit. Common AEs included drowsiness (25.0%), Parkinsonism (15.4%), depression (7.6%), and akathisia (7.6%). Comparison of log‐likelihood ratios revealed that age was a reliable predictor of Parkinsonism (P < 0.0001). TBZ is a safe and effective drug for the long‐term treatment of hyperkinetic movement disorders. © 2006 Movement Disorder Society
Url:
DOI: 10.1002/mds.21222
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001A85
- to stream Istex, to step Curation: 001A85
- to stream Istex, to step Checkpoint: 001874
- to stream PubMed, to step Corpus: 002966
- to stream PubMed, to step Curation: 002966
- to stream PubMed, to step Checkpoint: 002738
- to stream Ncbi, to step Merge: 001973
- to stream Ncbi, to step Curation: 001973
- to stream Ncbi, to step Checkpoint: 001973
- to stream Main, to step Merge: 003C88
- to stream PascalFrancis, to step Corpus: 001810
- to stream PascalFrancis, to step Curation: 001511
- to stream PascalFrancis, to step Checkpoint: 001609
- to stream Main, to step Merge: 004199
- to stream Main, to step Curation: 002D66
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long‐term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders</title><author><name sortKey="Kenney, Christopher" sort="Kenney, Christopher" uniqKey="Kenney C" first="Christopher" last="Kenney">Christopher Kenney</name></author><author><name sortKey="Hunter, Christine" sort="Hunter, Christine" uniqKey="Hunter C" first="Christine" last="Hunter">Christine Hunter</name></author><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name><affiliation><country>États-Unis</country><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName><orgName type="university" n="3">Baylor College of Medicine</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:D1E7C7713EC67AFBC3CB52E2FA24CACA4DF3D5CF</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/mds.21222</idno><idno type="url">https://api.istex.fr/document/D1E7C7713EC67AFBC3CB52E2FA24CACA4DF3D5CF/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001A85</idno><idno type="wicri:Area/Istex/Curation">001A85</idno><idno type="wicri:Area/Istex/Checkpoint">001874</idno><idno type="wicri:doubleKey">0885-3185:2007:Kenney C:long:term:tolerability</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:17133512</idno><idno type="wicri:Area/PubMed/Corpus">002966</idno><idno type="wicri:Area/PubMed/Curation">002966</idno><idno type="wicri:Area/PubMed/Checkpoint">002738</idno><idno type="wicri:Area/Ncbi/Merge">001973</idno><idno type="wicri:Area/Ncbi/Curation">001973</idno><idno type="wicri:Area/Ncbi/Checkpoint">001973</idno><idno type="wicri:doubleKey">0885-3185:2007:Kenney C:long:term:tolerability</idno><idno type="wicri:Area/Main/Merge">003C88</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:07-0133242</idno><idno type="wicri:Area/PascalFrancis/Corpus">001810</idno><idno type="wicri:Area/PascalFrancis/Curation">001511</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001609</idno><idno type="wicri:doubleKey">0885-3185:2007:Kenney C:long:term:tolerability</idno><idno type="wicri:Area/Main/Merge">004199</idno><idno type="wicri:Area/Main/Curation">002D66</idno><idno type="wicri:Area/Main/Exploration">002D66</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Long‐term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders</title><author><name sortKey="Kenney, Christopher" sort="Kenney, Christopher" uniqKey="Kenney C" first="Christopher" last="Kenney">Christopher Kenney</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Hunter, Christine" sort="Hunter, Christine" uniqKey="Hunter C" first="Christine" last="Hunter">Christine Hunter</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas</wicri:regionArea><placeName><region type="state">Texas</region></placeName><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName><orgName type="university" n="3">Baylor College of Medicine</orgName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-01-15">2007-01-15</date><biblScope unit="vol">22</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="193">193</biblScope><biblScope unit="page" to="197">197</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">D1E7C7713EC67AFBC3CB52E2FA24CACA4DF3D5CF</idno><idno type="DOI">10.1002/mds.21222</idno><idno type="ArticleID">MDS21222</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Age of Onset</term><term>Anti-Dyskinesia Agents (administration & dosage)</term><term>Anti-Dyskinesia Agents (adverse effects)</term><term>Anti-Dyskinesia Agents (therapeutic use)</term><term>Chorea</term><term>Drug Administration Schedule</term><term>Drug Tolerance (physiology)</term><term>Dyskinesia</term><term>Dyskinesia, Drug-Induced (drug therapy)</term><term>Dyskinesia, Drug-Induced (epidemiology)</term><term>Dyskinesia, Drug-Induced (physiopathology)</term><term>Female</term><term>Humans</term><term>Huntington Disease (epidemiology)</term><term>Huntington Disease (etiology)</term><term>Huntington Disease (physiopathology)</term><term>Hyperkinesia</term><term>Hyperkinesis (drug therapy)</term><term>Hyperkinesis (epidemiology)</term><term>Hyperkinesis (physiopathology)</term><term>Long term</term><term>Male</term><term>Middle Aged</term><term>Myoclonus (drug therapy)</term><term>Myoclonus (epidemiology)</term><term>Myoclonus (physiopathology)</term><term>Nervous system diseases</term><term>Parkinsonian Disorders (drug therapy)</term><term>Parkinsonian Disorders (epidemiology)</term><term>Parkinsonian Disorders (physiopathology)</term><term>Prevalence</term><term>Retrospective Studies</term><term>Severity of Illness Index</term><term>Tetrabenazine</term><term>Tetrabenazine (administration & dosage)</term><term>Tetrabenazine (adverse effects)</term><term>Tetrabenazine (therapeutic use)</term><term>Tic</term><term>Tics (drug therapy)</term><term>Tics (epidemiology)</term><term>Tics (physiopathology)</term><term>Time</term><term>Treatment</term><term>chorea</term><term>tardive dyskinesia</term><term>tetrabenazine</term><term>tics</term><term>tolerability</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anti-Dyskinesia Agents</term><term>Tetrabenazine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Anti-Dyskinesia Agents</term><term>Tetrabenazine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Dyskinesia Agents</term><term>Tetrabenazine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dyskinesia, Drug-Induced</term><term>Hyperkinesis</term><term>Myoclonus</term><term>Parkinsonian Disorders</term><term>Tics</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term><term>Huntington Disease</term><term>Hyperkinesis</term><term>Myoclonus</term><term>Parkinsonian Disorders</term><term>Tics</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Huntington Disease</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Drug Tolerance</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term><term>Huntington Disease</term><term>Hyperkinesis</term><term>Myoclonus</term><term>Parkinsonian Disorders</term><term>Tics</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Age of Onset</term><term>Drug Administration Schedule</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Prevalence</term><term>Retrospective Studies</term><term>Severity of Illness Index</term><term>Time</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Chorée syndrome</term><term>Dyskinésie</term><term>Hyperkinésie</term><term>Long terme</term><term>Système nerveux pathologie</term><term>Tic</term><term>Traitement</term><term>Tétrabénazine</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We sought to review the long‐term tolerability of tetrabenazine (TBZ) and seek determinants of tolerability in the treatment of hyperkinetic movement disorders. A retrospective chart review was performed on patients treated with TBZ between 1997 and 2004. Efficacy of TBZ was assessed by a 1‐ to 5‐point response scale (1 = marked reduction in abnormal movements, 5 = worsening). All adverse events (AEs) were captured according to their relationship with study drug. A total of 448 patients (42% male) were treated for a variety of hyperkinesias, including tardive dyskinesia (n = 149), dystonia (n = 132), chorea (n = 98), tics (n = 92), and myoclonus (n = 19). The mean age at onset of the movement disorder was 43.0 ± 24.2 years, with TBZ starting at a mean age of 50.0 ± 22.3 years. Patients remained on treatment for a mean of 2.3 ± 3.4 years. An efficacy response rating of 1 or 2 was sustained in the majority of patients between the first and last visit. Common AEs included drowsiness (25.0%), Parkinsonism (15.4%), depression (7.6%), and akathisia (7.6%). Comparison of log‐likelihood ratios revealed that age was a reliable predictor of Parkinsonism (P < 0.0001). TBZ is a safe and effective drug for the long‐term treatment of hyperkinetic movement disorders. © 2006 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Texas</li></region><settlement><li>Houston</li></settlement><orgName><li>Baylor College of Medicine</li></orgName></list><tree><country name="États-Unis"><region name="Texas"><name sortKey="Kenney, Christopher" sort="Kenney, Christopher" uniqKey="Kenney C" first="Christopher" last="Kenney">Christopher Kenney</name></region><name sortKey="Hunter, Christine" sort="Hunter, Christine" uniqKey="Hunter C" first="Christine" last="Hunter">Christine Hunter</name><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002D66 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002D66 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:D1E7C7713EC67AFBC3CB52E2FA24CACA4DF3D5CF
|texte= Long‐term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders
}}
| This area was generated with Dilib version V0.6.23. |  |